Company Snapshot: EMIS  Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services


Emisphere Technologies, Inc. to Hold Conference Call to Discuss First Quarter 2006 Financial Results

    TARRYTOWN, N.Y., May 1 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS) will hold a teleconference to discuss its
2006 first quarter financial results on Friday, May 5, 2006, beginning at
10:00 a.m. Eastern Time (7:00 a.m. Pacific). A replay of the call will be
accessible approximately two hours following the end of the call and will
be archived through May 12, 2006.
    The live conference call dial-in number is: 1-800-819-9193 (U.S./Canada)
                                                1-913-981-4911 (International)
    The live conference call ID number is:      6454497
    To access a replay of the call:             1-888-203-1112 (U.S./Canada)
                                                1-719-457-0820 (International)
    Conference replay PIN number is:            8928240
    Emisphere will simultaneously be webcasting this teleconference. To
access the live broadcast in listen-only mode or the subsequently archived
recording, please go to the Investor Relations portion of the Company's
website at: http://www.emisphere.com/ir.asp.
    Please visit the site at least five minutes prior to start time for
instructions.
    About Emisphere Technologies, Inc.
    Emisphere Technologies, Inc. is a biopharmaceutical company pioneering
the oral delivery of otherwise injectable drugs. Emisphere's business
strategy is to develop oral forms of injectable drugs, either alone or with
corporate partners, by applying its proprietary eligen(R) technology to
those drugs or licensing its eligen(R) technology to partners who typically
apply it directly to their marketed drugs. Emisphere's eligen(R) technology
has enabled the oral delivery of proteins, peptides, macromolecules and
charged organics. Emisphere and its partners have advanced oral
formulations or prototypes of salmon calcitonin, heparin, insulin,
parathyroid hormone, human growth hormone and cromolyn sodium into clinical
trials. Emisphere has strategic alliances with world-leading pharmaceutical
companies. For further information, please visit http://www.emisphere.com.


SOURCE Emisphere Technologies, Inc.




Back to Topback to top

Related links:
  • http://www.emisphere.com/ir.asp
  • http://www.emisphere.com
    CONTACT:
    Elliot M. Maza, CPA, J.D., Chief Financial
    Officer, Emisphere Technologies, Inc., +1-914-785-4703; Media:
    Dan Budwick, BMC Communications, +1-212-477-9007, ext. 14